In China you can get Ozempic and Wegovy within the hour for just $100 a month - MarketWatch
1. Chinese consumers increasingly access Ozempic for off-label weight loss. This boosts domestic demand. 2. Rapid delivery and lower prices drive high adoption in China's digital healthcare market. This improves market penetration. 3. Novo Nordisk maintains 80% GLP-1 market share in China. It supports sustained revenue growth. 4. U.S. pricing controversies and Senate scrutiny raise regulatory and reputational concerns. This may impact global sentiment.